Hua Medicine, a Chinese drug developer player that simultaneously closed its Series D and E funding rounds in March, has become the second company to file for a Hong Kong IPO under rules that allow zero revenue biotech businesses to go public.
No details are available as to the size and pricing of the offering. Hua’s filing comes a month after Ascletis announced plans to list. While lawyers and bankers say they are receiving a lot of inbound...
SeaLink Capital Partners has led a INR2 billion ($29 million) investment in Indian maternal and pediatric hospital chain Surya Children’s Medicare, providing an exit for OrbiMed Advisors.
Japan's governance reforms have given activist investors more leverage over underperforming companies. PE firms are well positioned to offer solutions to these targets in the form of carve-outs, privatizations, or partnerships
Chinese B2B pharmaceutical trading and education platform Yaoshibang has received RMB420 million ($65 million) in Series C funding across two tranches.
A group of VCs including China Growth Capital have agreed to invest $16 million in Ono, a China-based company that claims to be the creator of the first decentralized social network.